- Home
- ECBK vs CLLS Comparison
ECBK vs CLLS Comparison
Compare ECBK & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ECBK
- CLLS
- Stock Information
- Founded
- ECBK 1919
- CLLS 1999
- Country
- ECBK United States
- CLLS France
- Employees
- ECBK N/A
- CLLS N/A
- Industry
- ECBK Banks
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- ECBK Finance
- CLLS Health Care
- Exchange
- ECBK Nasdaq
- CLLS Nasdaq
- Market Cap
- ECBK 151.0M
- CLLS 143.4M
- IPO Year
- ECBK N/A
- CLLS 2007
- Fundamental
- Price
- ECBK $15.31
- CLLS $1.47
- Analyst Decision
- ECBK
- CLLS Buy
- Analyst Count
- ECBK 0
- CLLS 2
- Target Price
- ECBK N/A
- CLLS $7.00
- AVG Volume (30 Days)
- ECBK 15.8K
- CLLS 53.4K
- Earning Date
- ECBK 08-08-2025
- CLLS 08-05-2025
- Dividend Yield
- ECBK N/A
- CLLS N/A
- EPS Growth
- ECBK 17.87
- CLLS N/A
- EPS
- ECBK 0.57
- CLLS N/A
- Revenue
- ECBK $26,906,000.00
- CLLS $54,747,000.00
- Revenue This Year
- ECBK N/A
- CLLS $48.52
- Revenue Next Year
- ECBK N/A
- CLLS $5.17
- P/E Ratio
- ECBK $26.68
- CLLS N/A
- Revenue Growth
- ECBK 5.99
- CLLS 351.26
- 52 Week Low
- ECBK $12.36
- CLLS $1.10
- 52 Week High
- ECBK $16.99
- CLLS $2.43
- Technical
- Relative Strength Index (RSI)
- ECBK 42.79
- CLLS 53.84
- Support Level
- ECBK $15.05
- CLLS $1.33
- Resistance Level
- ECBK $15.51
- CLLS $1.46
- Average True Range (ATR)
- ECBK 0.42
- CLLS 0.07
- MACD
- ECBK -0.06
- CLLS 0.00
- Stochastic Oscillator
- ECBK 18.31
- CLLS 64.13
About ECBK ECB Bancorp Inc.
ECB Bancorp Inc operates as a bank holding company of Everett Co-operative Bank. The firm through its subsidiary engages in business consisting of taking deposits from the general public and investing those deposits, together with funds generated from operations, in one- to four-family residential real estate loans, commercial real estate, and multifamily real estate loans, construction and land loans and home equity lines of credit.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.